Cerebrospinal Fluid Biomarkers Can Play a Pivotal Role in the Diagnostic Work Up of Primary Progressive Aphasia

2014 ◽  
Vol 43 (4) ◽  
pp. 1429-1440 ◽  
Author(s):  
Roberto Santangelo ◽  
Elisabetta Coppi ◽  
Laura Ferrari ◽  
Maria Paola Bernasconi ◽  
Patrizia Pinto ◽  
...  
2016 ◽  
Vol 55 (4) ◽  
pp. 1453-1461 ◽  
Author(s):  
George P. Paraskevas ◽  
Dimitrios Kasselimis ◽  
Evie Kourtidou ◽  
Vasilios Constantinides ◽  
Anastasia Bougea ◽  
...  

2019 ◽  
Vol 33 (3) ◽  
pp. 282-284
Author(s):  
Giulia Perini ◽  
Matteo Cotta Ramusino ◽  
Elena Sinforiani ◽  
Diego Franciotta ◽  
Giusppe Trifirò ◽  
...  

2002 ◽  
Vol 333 (1) ◽  
pp. 33-36 ◽  
Author(s):  
Lienhard Maeck ◽  
Johannes Meller ◽  
Markus Otto ◽  
Gerthild Stiens ◽  
Jens Wiltfang ◽  
...  

2013 ◽  
Vol 7 (1) ◽  
pp. 2-9 ◽  
Author(s):  
Marsel Mesulam

ABSTRACT Primary progressive aphasia (PPA) is a clinical syndrome diagnosed when three core criteria are met. First, there should be a language impairment (i.e., aphasia) that interferes with the usage or comprehension of words. Second, the neurological work-up should determine that the disease is neurodegenerative, and therefore progressive. Third, the aphasia should arise in relative isolation, without equivalent deficits of comportment or episodic memory. The language impairment can be fluent or non-fluent and may or may not interfere with word comprehension. Memory for recent events is preserved although memory scores obtained in verbally mediated tests may be abnormal. Minor changes in personality and behavior may be present but are not the leading factors that bring the patient to medical attention or that limit daily living activities. This distinctive clinical pattern is most conspicuous in the initial stages of the disease, and reflects a relatively selective atrophy of the language network, usually located in the left hemisphere. There are different clinical variants of PPA, each with a characteristic pattern of atrophy. The underlying neuropathological diseases are heterogeneous and can include Alzheimer's disease as well as frontotemporal lobar degeneration. The clinician's task is to recognize PPA and differentiate it from other neurodegenerative phenotypes, use biomarkers to surmise the nature of the underlying neuropathology, and institute the most fitting multimodal interventions.


2018 ◽  
Vol 66 (1) ◽  
pp. 271-280 ◽  
Author(s):  
Géraldine Bera ◽  
Raffaella Migliaccio ◽  
Thibaut Michelin ◽  
Foudil Lamari ◽  
Sophie Ferrieux ◽  
...  

2019 ◽  
Vol 47 (10) ◽  
pp. 4968-4980 ◽  
Author(s):  
Tiziana Casoli ◽  
Susy Paolini ◽  
Paolo Fabbietti ◽  
Patrizia Fattoretti ◽  
Lucia Paciaroni ◽  
...  

Objective This study aimed to determine the most appropriate cognitive and cerebrospinal fluid (CSF) biomarker setting to distinguish frontotemporal dementia (FTD) from Alzheimer’s disease (AD). Method Patients with FTD, those with AD, and those without dementia were enrolled in this study. CSF amyloid-ß 42 (Aß42), total (t)-tau, and phosphorylated (p)-tau concentrations were determined by enzyme-linked immunosorbent assays. Cognition was evaluated by the Mini-Mental State Examination (MMSE) and its domain scores. The associations of CSF biomarkers with cognitive measures were examined using regression models and the diagnostic value of CSF biomarkers was determined by receiver operating characteristics curves. Results CSF Aß42 levels were lower, whereas t-tau/Aß42 and p-tau/Aß42 ratios were higher in patients with AD compared with those with FTD. Some MMSE domain scores were different in FTD and AD, but they did not improve the ability to distinguish between the two pathologies. Poor temporal orientation scores were associated with low Aß42 levels only in patients with FTD. The p-tau/Aß42 ratio reached sufficient levels of sensitivity and specificity to discriminate FTD with primary progressive aphasia from AD. Conclusions The ratio of CSF p-tau/Aß42 is a sensitive and specific biomarker for discriminating patients with primary progressive aphasia from those with AD.


2020 ◽  
Author(s):  
Shorena Janelidze ◽  
Erik Stomrud ◽  
Ruben Smith ◽  
Sebastian Palmqvist ◽  
Niklas Mattsson ◽  
...  

ABSTRACTCerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD) reflecting abnormal tau metabolism in the brain. Tau can be phosphorylated at multiple other sites including threonine 217, and here we investigated the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n=194), p-tau217 had stronger correlations with the tau PET tracer [18F]flortaucipir, and more accurately identified individuals with abnormally increased [18F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 were higher compared to p-tau181 and better correlated with [18F]flortaucipir retention. P-tau217 correlated better than p-tau181 with PET measures of neocortical amyloid-β burden and more accurately distinguished AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [18F]flortaucipir were corroborated in an independent EXPEDITION3 trial cohort (n=32). These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.


Sign in / Sign up

Export Citation Format

Share Document